We prospectively evaluated the capacity of serum procalcitonin (PCT), compared with serum levels of Creactive protein (CRP) and endotoxin, to identify children at high risk for mortality from sepsis after BMT. Of 47 pediatric bone marrow transplantation patients studied, 22 had an uneventful course post-transplant (Group 1), 17 survived at least one septic event (Group 2), and eight died from multiorgan failure (MOF) following septic shock (Group 3). Median concentrations of PCT over the course of the study were 1.3, 15.2, and 102.8 ng/ml, respectively, in each of the three groups (Po0.002 for each comparison). Median concentrations of CRP were 91, 213, and 260 mg/l, respectively (Po0.001 for Group 1 vs Group 2 and Group 3; P ¼ NS for Group 2 vs Group 3). Median concentrations of endotoxin were 0.21, 0.30, and 0.93 U/l, respectively (P ¼ NS for each comparison). Median concentrations of PCT, in contrast to serum CRP and endotoxin, correlated with the severity of sepsis (8.2 ng/ml in 'sepsis' and 22.3 ng/ml in 'severe sepsis', P ¼ 0.028) and provided useful prognostic information during septic episodes.
sepsis; children; survival; neutropenia; infection; shock The rate of death from severe sepsis ranges from 30 to 50% despite advances in critical care. 1 In the United States, approximately 750 000 cases of sepsis occur each year, at least 225 000 of which are fatal. 2 Susceptibility to infection has posed one of the most formidable challenges in the clinical management of patients undergoing bone marrow transplantation (BMT). 3, 4 The outcome of sepsis in children undergoing BMT needs to be improved. Novel treatment strategies have been developed, targeting cytokines as mediators of sepsis. 5, 6 The paucity of robust, objective criteria by which to judge the efficacy of new approaches has been a significant obstacle to conducting clinical trials. The ideal serum biochemical parameter would be specifically elevated during all septic events, the degree of its release would correlate with the severity of the sepsis, and its measurement would be straightforward and cost-effective.
Recently, there has been considerable interest in serum procalcitonin (PCT) in the setting of infectious and inflammatory conditions. Serum PCT measurement has allowed discrimination between episodes of fever caused by bacteria, fungi, and parasites from fevers of viral and noninfectious etiologies. [7] [8] [9] In addition, serum PCT levels have been found to correlate with severity in bacterial, fungal, and parasitic infections. 10, 11 In this study of pediatric BMT recipients, it was our goal to address the following questions: (1) Are serum levels of PCT specifically elevated during a septic episode? (2) Does severity of sepsis correlate with serum levels of PCT? (3) How predictive are serum PCT levels for the outcome of a septic event? We sought to compare serum levels of PCT with those of the acute-phase reactant C-reactive protein (CRP), the 'gold standard' inflammatory marker, 12 and serum levels of endotoxin, a known trigger for severe septic events. 13 To our knowledge, this is the first study to prospectively evaluate the role of PCT in sepsis risk assessment among children after BMT.
Materials and methods

Patients and transplant characteristics
The study was approved by the Institutional Research Board. We enrolled 47 consecutive patients who were admitted for BMT to the Department of Pediatrics, Friedrich-Schiller-University Jena, Germany between 1997 and 1999. Patient characteristics are summarized in Table 1 . All patients older than two years of age receiving allogeneic grafts were conditioned with total body irradiation (total of 1320 cGy over four consecutive days) and cyclophosphamide (120 mg/kg i.v. over two consecutive days); patients under the age of 2 years received busulfan (1.0 mg/kg/dose i.v. every 6 h over 2 h on four consecutive days) in place of total body irradiation. Autologous BMT patients received busulfan and melphalan-based regimens. Grafts used for the allogeneic transplants were T-cell replete. Graftversus-host disease (GVHD) prophylaxis consisted of prednisone, short-course methotrexate, and cyclosporin. 14 Every patient received recombinant human granulocyte colony-stimulating factor (G-CSF; 5 mg/kg/day) from day +1 post-transplant until an absolute neutrophil count (ANC) of at least 2500/ml was attained for three consecutive days. The day of engraftment was defined as the first of two consecutive days with an ANC of at least 500/ml. All patients received infection prophylaxis consisting of cefazolin, ciprofloxacin, fluconazole, and nystatin. Patients were switched empirically to broad-spectrum antibiotic coverage when the axillary temperature equaled or exceeded 38.01C. Blood cultures were obtained up to three times a day when axillary temperature exceeded 38.01C. Antibiotic treatment was adjusted as necessary when positive blood cultures were obtained, retaining broad-spectrum coverage. On the fourth day of persisting fevers, therapy with amphotericin B was empirically initiated. Risk assessment for sepsis after bone marrow transplantation M Sauer et al
Sampling and clinical data collection
Enrolled patients were studied with daily serum sampling and detailed clinical evaluation from the day of graft infusion (day 0) through day 30 post-transplant. Serum was obtained each day from peripheral blood drawn from the central venous catheter at 7:00 a.m. All children were assessed by means of a standardized physical examination conducted by one of three physicians on a daily basis, between 9:00 a.m and noon. Examination findings were documented in a standardized fashion.
PCT, CRP, and endotoxin assays
Serum concentrations of PCT were determined by an immunoluminometric assay (LUMItest PCT) according to the manufacturer's specifications (BRAHMS Diagnostica, Berlin, Germany). The detection limit was 0.08 ng/ml. 15 CRP was determined in serum samples by an immunonephelometric method (Beckman Synchron CX-Systems) (REF). Levels o5 mg/ml were considered to be normal. 12 Endotoxin concentrations were assessed using a quantitative chromogenic limulus amebocyte lysate assay (QCL-1000, Whittaker M.A. Bioproducts, Walkersville, MD, USA). The detection limit for endotoxin was 0.015 EU/ml. 16 
Outcomes and analysis
Sepsis was defined according to the ACCP/SCCM definitions. The ACCP/SCCM defined sepsis as the systemic response to infection that is manifested by two or more of the following conditions as a result of infection: temperature 4381C or o361C; heart rate 490 beats/min; respiratory rate 420 breaths/min, or PaCO 2 o32 Torr (o4.3 kPa); white blood cell count 412 000 cells/ml, o4000 cells/ml, or with 410% 'immature (band) forms'. 17 Adjustments for a pediatric population were made. Respiratory rate and heart rate were reported to be consistent with the ACCP/SCCM criteria if they differed from a normal age-matched pediatric population by more than 50%. Since leukocyte count was not an appropriate criterion in the BMT setting, we excluded this criterion from the definition. Patients were divided into three groups according to their clinical status over the course of the study. Group 1 consisted of all the children who did not become septic during the observation period. Group 2 included all patients with sepsis who recovered from this event. Group 3 included all children who died during or following a septic episode. For severity of sepsis analyses, patients in Group 2 were further subdivided into a 'sepsis group' and a 'severe sepsis group'. 'Severe sepsis' was defined as follows, according to the AACP/SCCM Consensus Conference Criteria of 1992:
17 sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion and perfusion abnormalities may include, but were not limited to, lactic acidosis, oliguria, or an acute alteration in mental status.
In accordance with published norms, the following cutoff levels for serum PCT, CRP, and endotoxin, above which levels were deemed 'significantly elevated', were used: 1.0 ng/ml, 50 mg/l, and 0.1 EU/ml, respectively. 9,12,13 Using these thresholds, sensitivity and specificity were calculated.
Data were analyzed with a commercial computer software package (SigmaStat version 2.0; SPSS Science). Comparisons of group differences for continuous variables were made using the Kruskal-Wallis ANOVA on ranks. Mann-Whitney U-tests were used for pairwise comparisons. A Pp0.05 was considered significant. Results are given as median concentrations, with ranges between 25th and 75th percentiles provided in parenthesis.
Results
In total, 47 children were observed for 30 days after BMT. The observational time period of the first 30 days posttransplant was subdivided into 10-day intervals. The very early interval included days 0-9 where the patients were expected to develop aplasia, the following interval stretched from days 10 to 19 when engraftment was most likely to be achieved, and the last interval included days 20-30 as a time frame where stable white count recovery was expected. No patients had any measurable white blood cell counts before day 10 after transplant. All patients achieved stable engraftment (ANC4500/ml) between 15 and 30 days post-BMT.
Out of the 47 children, 22 (47%) were not diagnosed with sepsis (Group 1). None of these patients died. In all, 17 children (36%) experienced a septic event (Group 2) and subsequently recovered from it. Eight children (17%) were diagnosed with sepsis, developed multiorgan failure (MOF), and died (Group 3). All children with a fatal outcome had engrafted at the time of death.
The patients with a positive blood culture (16 of the 25 patients with documented sepsis) are summarized in Table 2 . In Table 3 , the organisms cultured (180 Gram positive and 68 Gram negative) and the origin of the cultures are further specified.
Serum PCT
Over the course of the study, children in Group 1 had a median serum PCT concentration of 1.3 ng/ml (0.45-2.1 ng/ ml). Patients in Group 2 had a median PCT concentration of 15.2 ng/ml (10.4-27.3 ng/ml) (Po0.001). Children in Group 3 had a median PCT concentration of 102.8 ng/ml (16.7-173.2 ng/ml) (Po0.001 vs Group 1; P ¼ 0.002 vs Risk assessment for sepsis after bone marrow transplantation M Sauer et al Group 2) . Within Group 2, there was a significant difference in serum PCT levels between those with 'sepsis' and 'severe sepsis' (8.2 and 22.3 ng/ml, respectively; P ¼ 0.028) (Figure 1 ). With the threshold set at 1.0 ng/ml, serum PCT yielded a sensitivity of 56% and a specificity of 87% to differentiate patients with sepsis from those without sepsis (Table 4) . The relative risk of death during a septic episode was 3.7 (95% confidence interval: 2.4-4.8) among patients with PCT serum levels 41.0 ng/ml. Setting the threshold at 10.0 ng/ml, the relative risk for a fatal outcome was increased to 26.4 (95% confidence interval: 19.6-31.4).
Serum CRP
Over the course of the study, children in Group 1 had a median serum CRP concentration of 91 mg/l (22 mg/l-165 mg/l). Patients in Group 2 had a median CRP concentration of 213 mg/l (153-224 mg/l) (Po0.001). Children in Group 3 had a median CRP concentration of 260 mg/l (179-324 mg/l) (Po0.001 vs Group 1; P ¼ NS vs Group 2). Within Group 2, there was no significant difference in serum CRP levels between those with 'sepsis' and 'severe sepsis' (Figure 2) .
With the threshold set at 50 mg/l, serum CRP yielded a sensitivity of 100% and a specificity of 41% to differentiate patients with sepsis from those without sepsis (Table 4) . The relative risk of death during a septic episode was 4.0 (95% confidence interval: 2.3-6.4) among patients with PCT serum levels 450 mg/l. Setting the threshold at 200 mg/l, the relative risk for a fatal outcome remained unchanged.
Serum endotoxin
Over the course of the study, children in Group 1 had a median serum endotoxin concentration of 0.21 U/l (0.08-0.34 U/l). Patients in Group 2 had a median endotoxin concentration of 0.3 U/l (0.12-0.82 U/l). Children in Group 3 had a median endotoxin concentration of 0.93 U/l (0.33-1.47 U/l).There was no significant difference between any of the three groups (Figure 3) .
With the threshold set at 0.1 U/l, serum endotoxin yielded a sensitivity of 90% and a specificity of 30% to differentiate patients with sepsis from those without sepsis (Table 4 ). The relative risk of death during a septic episode was 2.2 (95% confidence interval: 1.6-4.1) among patients with endotoxin levels 40.1 U/l. Setting the threshold at Serum procalcitonin levels (ng/ml) Figure 1 Procalcitonin-serum procalcitonin levels are shown as 25-75th percentile (box) and 5-95th percentile. Children that recovered from their sepsis (Group 2 in the text, n ¼ 17) were further subdivided into children with sepsis and children with severe sepsis. Serum PCT concentration during sepsis, severe sepsis, and septic shock differed significantly (Po0.01). percentile (Box) and 5-95th percentile. Children that recovered from their sepsis (group 2 in the text, n ¼ 17) were further subdivided into children with sepsis and children with severe sepsis. Serum PCT concentration during sepsis, severe sepsis, and septic shock did not differ significantly.
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Discussion
We have shown that serum PCT, unlike serum CRP or endotoxin, correlates with the severity of sepsis in pediatric HSCT recipients and, furthermore, that it identifies patients at high risk of a fatal outcome. In contrast, serum PCT did not prove to be a valuable tool for identifying sepsis at its onset in these patients, with a sensitivity of only 56%. The high sensitivity (100%) of CRP in this regard, which is consistent with results obtained in immunocompetent 18, 19 and incompetent adults, 9 must be interpreted in the context of its relatively low specificity (41%, compared to 87% with PCT).
Serum endotoxin was the least discriminating of the parameters we measured. Its elevation was neither very specific for sepsis nor was it a useful tool for risk assessment. The latter finding contrasts with data from other groups. 13, 20, 21 There could be two explanations for this. First, only one septic patient had a blood culture positive for Gram-negative bacteria. This distribution of infectious agents reflects the shift towards infections caused by Gram-positive bacteria increasingly seen in immunocompromised patients. 22 The second reason may be the short half-life of endotoxin. 23 A short serum endotoxin peak has been shown to be sufficient to trigger a complex cascade of cytokines that can finally result in severe septic complications. 24 If the serum sample is not collected within a very narrow window, endotoxinemia will not be identified. It is possible that we missed this window.
During the last two decades, mounting evidence has suggested that the organ injury and mortality resulting from sepsis is to a large extent caused by the explosive release of inflammatory mediators. 25 Interleukin-6 (IL-6) and interleukin-8 (IL-8) are potent inflammatory mediators, and their plasma concentrations have been tested as prognostic factors in several studies. 26, 27 These cytokines have not discriminated reliably between patients with infectious and noninfectious diseases. Elevated IL-8 levels were predictive of MOF and an increased likelihood of death in one study. 18 Van Dissel et al 19 examined serum PCT, interleukin-10 (IL-10), and tumor necrosis factor-a (TNF-a) among an adult patient population admitted for fever and found PCT to be superior in identifying high-risk patients with infection.
New treatment strategies are being developed that specifically target these sepsis-related cytokine cascades, 5 or substitute factors, such as activated protein C, that are known to be modulators of the inflammation associated with severe sepsis. 28 For patients undergoing BMT, such clinical trials are urgently needed. Major obstacles to the implementation of these studies, however, have been the lack of reliable objective tools for the grading of sepsis, and for the determination of efficacy of novel treatments. Defining 'sepsis' and 'severe sepsis' in a meaningful way in this pediatric population is exceptionally challenging. In 1992, the American College of Chest Physicians and the Society of Critical Care Medicine published consensus definitions of 'severe inflammatory response syndrome' (SIRS), 'sepsis', and 'severe sepsis'. 17 The criteria provided in these consensus definitions provide tools that will not distinguish between fever and sepsis in these cytopenic patients, let alone sepsis and severe GvHD. Despite these significant limitations, we decided to use these criteria in this study because they are the only widely accepted ones. Other clinical scoring systems have been developed, 6, 29, 30 but they are highly examiner-dependent, limiting their use in multicenter trials.
In conclusion, we have shown that serum PCT correlates with the severity of sepsis among profoundly immunocompromised pediatric BMT recipients, and that it may reliably identify children at high risk for mortality. Our findings suggest that monitoring serum PCT could play a valuable role in clinical trials of novel sepsis therapies in this setting, as an objective tool to grade severity. Serum endotoxin levels (EU/ml) Figure 3 Endotoxin-serum endotoxin levels are shown as 25-75th percentile (box) and 5-95th percentile. None of the four groups pictured in this figure was significantly different.
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